1)Minds診療ガイドライン作成マニュアル編集委員会:Minds診療ガイドライン作成マニュアル2020 ver.3.0.公益財団法人日本医療機能評価機構EBM医療情報部,2021
2)日本神経精神薬理学会,日本臨床精神神経薬理学会:統合失調症薬物治療ガイドライン2022.医学書院,2022
3)日本うつ病学:うつ病治療ガイドライン,第2版.医学書院,2017
4)Takaesu Y, Watanabe K, Numata S, et al:Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment(EGUIDE)” project:A nationwide dissemination, education and evaluation study. Psychiatry Clin Neurosci 73:642-648, 2019[PMID:31437336]
5)Yamada H, Motoyama M, Hasegawa N, et al:A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders:The Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment(EGUIDE)project. BJPsych Open 8:e83, 2022[PMID:35446248]
6)Numata S, Nakataki M, Hasegawa N, et al:Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep 41:199-206, 2021[PMID:33704931]
7)Ogasawara K, Numata S, Hasegawa N, et al:Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacol Rep 42:221-225, 2022[PMID:35272393]
8)Iida H, Iga J, Hasegawa N, et al:Unmet need for major depressive disorders-Findings from the ‘Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment(EGUIDE)' project:A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci 74:667-669, 2020[PMID:32881226]
9)Ichihashi K, Hori H, Hasegawa N, et al:Prescription patterns in patients with schizophrenia in Japan:first-quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment(EGUIDE)” project. Neuropsychopharmacol Rep 40:281-286, 2020[PMID:32602667]
10)Inada K, Fukumoto K, Hasegawa N, et al:Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacol Rep 42:502-509, 2022[PMID:362554805]
11)Fukumoto K, Kodaka F, Hasegawa N, et al:Development of an individual fitness score(IFS)based on the depression treatment guidelines of in the Japanese Society of Mood Disorders. Neuropsychopharmacol Rep 43:33-39,2023[PMID:36394160]